Status:
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Eligibility Criteria
Inclusion
- type 2 diabetes
- BMI 20-45kg/m2 inclusive
Exclusion
- females who are pregnant, lactating, or less than 6 weeks post-partum
- current symptomatic heart failure (NYHA Class II-IV)
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
685 Patients enrolled
Trial Details
Trial ID
NCT00839527
Start Date
February 1 2009
End Date
April 1 2013
Last Update
January 9 2017
Active Locations (358)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Alabaster, Alabama, United States, 35007
2
GSK Investigational Site
Birmingham, Alabama, United States, 35205
3
GSK Investigational Site
Birmingham, Alabama, United States, 35235
4
GSK Investigational Site
Birmingham, Alabama, United States, 35242